Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.

This review discusses the efficacy and safety of intralesional triamcinolone acetonide for treating acne keloidalis nuchae, highlighting its significant effectiveness with rare side effects when used properly.

This review discusses the repurposing of auranofin for oncological and non-oncological uses and highlights its early-stage clinical trial findings, suggesting further exploration of its therapeutic potential.

This study suggests that trichoscopic features, such as perifollicular erythema and cicatricial white patches, are independently associated with pruritus and the severity of frontal fibrosing alopecia.

This study found that intralesional injection of triamcinolone acetonide combined with latanoprost (a PGF2α analog) was more effective in treating localized alopecia areata, showing higher treatment response rates and greater reduction in severity scores compared to other treatments.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This case report suggests that intradermal botulinum toxin type A may alleviate pruritus and reduce papules in Fox-Fordyce disease, improving quality of life without serious adverse effects for at least six months.

This study found that quaternary ammonium iminofullerenes (IFQA) can alleviate oxidative stress in maize caused by hydrogen peroxide, promoting root growth by enhancing antioxidant cycles and reducing ROS accumulation.

This study found that compound 3 derived from aza-bicyclo-carboxylic acid may exert a cardioprotective effect by reducing infarction area in myocardial ischemia-reperfusion injury, potentially involving A1-adenosine receptor activation and changes in cAMP levels.

This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.

This study evaluated the antimicrobial activity of a newly synthesized fluoroquinolone against Staphylococcus, Streptococcus, and Escherichia coli strains. The researchers compared results from the microdilution technique and agar disk diffusion method to EUCAST's recommended breakpoint values, building on promising in silico molecular docking tests.

This study found that doxorubicin-induced oxidative stress downregulates FLIPs and phosphorylates EF2, sensitizing prostate cancer cells to TRAIL; antioxidants may reduce doxorubicin's effectiveness, warranting further investigation.

This study presents two cases where intralesional methotrexate combined with ablative fractional CO2 laser treatment resulted in excellent outcomes for refractory alopecia areata.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

This study suggests that the C-terminal of AHF is crucial for its binding to keratin bundles and modulating the keratin meshwork in hair follicles.

This case study suggests that trichoscopic examination of the beard can aid in diagnosing frontal fibrosing alopecia in men, especially when challenging to differentiate from androgenetic alopecia.

This study identifies specific trichoscopic features such as empty follicles and perifollicular erythema in Caucasians with frontal fibrosing alopecia, which may assist in diagnosis and monitoring, but stresses the need for further research due to limited demographic data.

This study found that frontal fibrosing alopecia involves distinct molecular changes, such as downregulation of steroid and cholesterol pathways and upregulation of fibrotic and immune response genes, which may help guide treatment strategies.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

The researchers in this study identified molecular mechanisms involved in frontal fibrosis alopecia, highlighting immune response and fatty acid metabolism, and developed a four-gene diagnostic model showing high accuracy in distinguishing affected individuals from controls.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

In this ex vivo and mouse model study, Tofacitinib-loaded nanoparticles demonstrated enhanced delivery of the drug into hair follicles and reduced inflammatory effects compared to conventional forms, indicating potential for safer, topical use in treating alopecia areata.

This review discusses the phytochemistry, pharmacology, pharmacokinetics, and standardization of Forsythiae Fructus, detailing both unripe and ripe forms, but reports no new clinical results.

This case report describes a woman with frontal fibrosing alopecia who did not improve with hydroxychloroquine and topical minoxidil but achieved clinical stabilization with methotrexate monotherapy.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

In this study, oral tranexamic acid significantly improved melasma in 40 female patients over three months, with no adverse effects like post-inflammatory hyperpigmentation or bleeding, demonstrating its potential as a safe and effective treatment option.

In this study on patchy alopecia areata treatment involving 20 patients, TCA (triamcinolone acetonide) injections showed a significantly better response and minimal side effects compared to superficial cryotherapy.

Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.